https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results-report BiopharmaWatch en 2026-09-22T00:00:00.000Z Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 https://www.biopharmawatch.com/news/NVS/novartis-positive-chmp-opinion-cosentyx-pmr BiopharmaWatch en 2026-09-18T14:51:00.000Z Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR) https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-otc-deficiency-phase-2-update BiopharmaWatch en 2026-09-18T13:00:00.000Z Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-direct-offering-september-2026 BiopharmaWatch en 2026-09-18T13:00:00.000Z Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules https://www.biopharmawatch.com/news/SILO/silo-pharma-us-patent-allowance-spc-15-ptsd-treatment BiopharmaWatch en 2026-09-18T12:50:00.000Z Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio https://www.biopharmawatch.com/news/ONMD/onemednet-reports-record-bookings-faster-fulfillment BiopharmaWatch en 2026-09-18T12:35:00.000Z OneMedNet Reports Record Bookings as Faster Fulfillment Begins https://www.biopharmawatch.com/news/ABBV/abbvie-vraylar-real-world-data-psych-congress-2026 BiopharmaWatch en 2026-09-18T12:30:00.000Z AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026 https://www.biopharmawatch.com/news/LABT/lakewood-amendex-phase-2a-trial-nu-3-diabetic-foot-ulcers BiopharmaWatch en 2026-09-18T12:13:00.000Z Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers https://www.biopharmawatch.com/news/CORT/corcept-chmp-opinion-relacorilant-eu-authorization BiopharmaWatch en 2026-09-18T12:00:00.000Z Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) https://www.biopharmawatch.com/news/ABEO/abeona-congratulates-ultragenyx-fayuvi-approval BiopharmaWatch en 2026-09-18T11:30:00.000Z Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) https://www.biopharmawatch.com/news/PODD/insulet-bernstein-healthcare-forum-2026 BiopharmaWatch en 2026-09-18T11:00:00.000Z Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum https://www.biopharmawatch.com/news/BSEM/biostem-technologies-secures-40-million-equity-facility BiopharmaWatch en 2026-09-18T11:00:00.000Z BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-09-18T11:00:00.000Z BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/JNJ/chmp-recommends-approval-tecvayli-teclistamab BiopharmaWatch en 2026-09-18T11:00:00.000Z CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-third-quarter-2026-results BiopharmaWatch en 2026-09-18T10:59:00.000Z Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 https://www.biopharmawatch.com/news/MRK/merck-positive-eu-chmp-opinion-keytruda-padcev-mibc BiopharmaWatch en 2026-09-18T10:55:00.000Z Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) https://www.biopharmawatch.com/news/MRK/merck-launches-your-hive-of-whole-health-hiv-support BiopharmaWatch en 2026-09-18T10:45:00.000Z Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV https://www.biopharmawatch.com/news/NTRA/largest-mrd-study-lung-cancer-signatera BiopharmaWatch en 2026-09-18T10:00:00.000Z Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM https://www.biopharmawatch.com/news/TAK/takeda-global-csr-climate-health-systems BiopharmaWatch en 2026-09-18T05:00:00.000Z Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-upsized-private-offering-convertible-notes BiopharmaWatch en 2026-09-18T03:20:00.000Z Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-public-offering-closure BiopharmaWatch en 2026-09-18T01:55:00.000Z Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering https://www.biopharmawatch.com/news/LINC/lincoln-educational-securities-class-action-lawsuit BiopharmaWatch en 2026-09-17T22:40:00.000Z LINCOLN EDUCATIONAL SERVICES CORP. (NASDAQ: LINC) INVESTORS: Hagens Berman Alerts Investors to Securities Class Action Lawsuit, Encourages LINC Shareholders with Losses to Contact the Firm https://www.biopharmawatch.com/news/BTMD/biotech-social-advisory-board-financial-innovation BiopharmaWatch en 2026-09-17T22:17:00.000Z BioTech Social Announces Advisory Board to Advance Financial Innovation for Life Science Companies https://www.biopharmawatch.com/news/ICUI/otsuka-icumed-recall-sodium-chloride-injection BiopharmaWatch en 2026-09-17T21:08:00.000Z Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-provides-update-private-placement-3-0-million BiopharmaWatch en 2026-09-17T21:05:00.000Z Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-private-placement-update BiopharmaWatch en 2026-09-17T21:05:00.000Z Marvel Biosciences fait le point sur un placement privé pouvant atteindre 3 millions de dollars https://www.biopharmawatch.com/news/NMAD/nomad-power-solutions-expands-business-disclosure-merger BiopharmaWatch en 2026-09-17T20:57:00.000Z NOMAD POWER SOLUTIONS FILES EXPANDED BUSINESS AND FINANCIAL DISCLOSURE FOLLOWING COMPLETION OF MERGER https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-17T20:30:00.000Z Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/INFU/infusystem-host-investor-webcast-september-2026 BiopharmaWatch en 2026-09-17T20:30:00.000Z InfuSystem to Host Investor Webcast on September 24, 2026 https://www.biopharmawatch.com/news/BIIB/phase-3-empaveli-data-reduction-proteinuria-kidney-function BiopharmaWatch en 2026-09-17T20:15:00.000Z Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-alisca-lung2-phase-ii-trial BiopharmaWatch en 2026-09-17T20:07:00.000Z Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer https://www.biopharmawatch.com/news/BBNX/beta-bionics-closes-172-5-million-offering BiopharmaWatch en 2026-09-17T20:05:00.000Z Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/ARGX/argenx-extraordinary-general-meeting-results BiopharmaWatch en 2026-09-17T20:03:00.000Z argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors https://www.biopharmawatch.com/news/XENE/xenon-azetukalner-nda-focal-seizures-update BiopharmaWatch en 2026-09-17T20:01:00.000Z Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-appoints-karen-vousden-board BiopharmaWatch en 2026-09-17T20:00:00.000Z Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors https://www.biopharmawatch.com/news/RARE/ultragenyx-fayuvi-approval-sanfilippo-syndrome BiopharmaWatch en 2026-09-17T19:48:43.000Z Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) https://www.biopharmawatch.com/news/HCTI/hcti-joins-kanzun-arcb-growth-fund-malaysia-us-corridor BiopharmaWatch en 2026-09-17T19:45:00.000Z Healthcare Triangle (Nasdaq: HCTI) Joins Kanzun-ARCB Growth Fund to Build Malaysia-to-US Corridor for AI and Healthcare Companies https://www.biopharmawatch.com/news/ABT/abbott-411th-consecutive-quarterly-dividend BiopharmaWatch en 2026-09-17T16:43:00.000Z Abbott declares 411th consecutive quarterly dividend https://www.biopharmawatch.com/news/BETR/betterlife-pharma-100-million-offering BiopharmaWatch en 2026-09-17T14:41:00.000Z BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-acquisition-marea-therapeutics BiopharmaWatch en 2026-09-17T13:26:00.000Z Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement https://www.biopharmawatch.com/news/VNRX/volitionrx-detectseps-launch-france BiopharmaWatch en 2026-09-17T13:17:00.000Z VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France https://www.biopharmawatch.com/news/LEXX/lexaria-updates-financial-position BiopharmaWatch en 2026-09-17T13:13:29.000Z Lexaria Updates Financial Position https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-1-2-million-offering BiopharmaWatch en 2026-09-17T13:10:00.000Z Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering https://www.biopharmawatch.com/news/POCI/precision-optics-engineering-order-satellite-customer BiopharmaWatch en 2026-09-17T13:00:00.000Z Precision Optics Announces Initial Engineering Order from New Satellite Optical Communications Customer https://www.biopharmawatch.com/news/CELZ/creative-medical-expands-ultrasome-patent-portfolio BiopharmaWatch en 2026-09-17T13:00:00.000Z Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing https://www.biopharmawatch.com/news/CODX/co-diagnostics-participate-who-unitaid-unaids-meeting BiopharmaWatch en 2026-09-17T13:00:00.000Z Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026 https://www.biopharmawatch.com/news/SGRY/surgery-partners-sale-idaho-falls-facilities-intermountain-health BiopharmaWatch en 2026-09-17T13:00:00.000Z Surgery Partners Completes Sale of Ownership Interests in Idaho Falls Facilities to Intermountain Health; Updates Guidance to Include Impact of the Transaction https://www.biopharmawatch.com/news/NTHI/neonc-eliminates-dilution-risk-clinical-advancements BiopharmaWatch en 2026-09-17T12:54:00.000Z NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-appoints-robert-spiegel-board BiopharmaWatch en 2026-09-17T12:42:00.000Z Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-engages-executives-drug-development BiopharmaWatch en 2026-09-17T12:32:00.000Z Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth https://www.biopharmawatch.com/news/TELO/telomir-zinc-visual-function-amd BiopharmaWatch en 2026-09-17T12:30:00.000Z Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) https://www.biopharmawatch.com/news/QTI/qt-imaging-appoints-dr-mark-winkler-cmo BiopharmaWatch en 2026-09-17T12:30:00.000Z QT Imaging Appoints Imaging Industry Veteran Dr. Mark Winkler as Chief Medical Officer https://www.biopharmawatch.com/news/ABBV/abbvie-phase-3-etentamig-results-ims-2026 BiopharmaWatch en 2026-09-17T12:30:00.000Z AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting https://www.biopharmawatch.com/news/FBLG/fibrobiologics-private-placement-closing BiopharmaWatch en 2026-09-17T12:30:00.000Z FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer https://www.biopharmawatch.com/news/SLGL/sol-gel-technologies-phase-3-trial-sgt-610-gorlin-syndrome BiopharmaWatch en 2026-09-17T12:30:00.000Z Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-hope3-presentation-wms-2026 BiopharmaWatch en 2026-09-17T12:30:00.000Z Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-ketamir-2-phase-2a-cipn BiopharmaWatch en 2026-09-17T12:30:00.000Z MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review https://www.biopharmawatch.com/news/LTRN/lantern-pharma-open-medicine-ai-webinar-september-2026 BiopharmaWatch en 2026-09-17T12:20:00.000Z Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23 https://www.biopharmawatch.com/news/VNRX/volitionrx-launch-detectseps-program-france BiopharmaWatch en 2026-09-17T12:17:00.000Z VolitionRx Participates in Launch of DETECSEPS Program in France https://www.biopharmawatch.com/news/CING/cingulate-smart-launch-indegene-summit BiopharmaWatch en 2026-09-17T12:05:00.000Z Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma https://www.biopharmawatch.com/news/NTHI/neonc-technologies-redeems-series-a-preferred-stock BiopharmaWatch en 2026-09-17T12:00:33.000Z NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution https://www.biopharmawatch.com/news/CRL/charles-river-rapid-cell-banking-innovation BiopharmaWatch en 2026-09-17T12:00:00.000Z Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines https://www.biopharmawatch.com/news/BIAF/bioaffinity-hong-kong-patent-cypath-lung-diagnostic BiopharmaWatch en 2026-09-17T12:00:00.000Z bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic https://www.biopharmawatch.com/news/ABBV/allergan-aesthetics-skin-quality-improvements BiopharmaWatch en 2026-09-17T12:00:00.000Z Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications https://www.biopharmawatch.com/news/ADPT/nccn-guidelines-update-multiple-myeloma-clonoseq BiopharmaWatch en 2026-09-17T12:00:00.000Z Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® https://www.biopharmawatch.com/news/VTAK/catheter-precision-locket-expansion-latin-america BiopharmaWatch en 2026-09-17T12:00:00.000Z Catheter Precision Expands LockeT Commercialization Across Latin America Following Successful Launch in Brazil https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-17T12:00:00.000Z Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-virtual-kol-event-lam-001 BiopharmaWatch en 2026-09-17T12:00:00.000Z Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026 https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-phase-1-trial-hmb-003 BiopharmaWatch en 2026-09-17T12:00:00.000Z Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding https://www.biopharmawatch.com/news/ELAN/elanco-bofa-securities-global-healthcare-conference-2026 BiopharmaWatch en 2026-09-17T11:57:00.000Z Elanco to Participate in BofA Securities Global Healthcare Conference 2026 https://www.biopharmawatch.com/news/RHEL/rhelion-filament-health-pex010-agreement-chdr-study BiopharmaWatch en 2026-09-17T11:52:00.000Z Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the Centre for Human Drug Research for PEX010 in a Study of Low and Medium Dose Psilocybin https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-evoke-platform-radial-ai-native-os BiopharmaWatch en 2026-09-17T11:50:00.000Z Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine https://www.biopharmawatch.com/news/CMND/clearmind-fda-psychedelic-hearing-2026 BiopharmaWatch en 2026-09-17T11:42:00.000Z Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. https://www.biopharmawatch.com/news/NUVB/nuvation-bio-fda-approval-ibtrozi-taletrectinib BiopharmaWatch en 2026-09-17T11:30:00.000Z Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-pedmark-results-siope-2026 BiopharmaWatch en 2026-09-17T11:30:00.000Z Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 https://www.biopharmawatch.com/news/KALA/kala-bio-yenvy-truong-advisory-team BiopharmaWatch en 2026-09-17T11:30:00.000Z KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team https://www.biopharmawatch.com/news/NVO/orbis-novo-nordisk-drug-discovery-partnership BiopharmaWatch en 2026-09-17T11:00:00.000Z Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion https://www.biopharmawatch.com/news/CVS/aetna-expands-bundled-oncology-prior-authorizations BiopharmaWatch en 2026-09-17T11:00:00.000Z Aetna expands bundled oncology prior authorizations, easing provider burden and accelerating member access to care https://www.biopharmawatch.com/news/PLSM/pulsenmore-expands-fertility-platform-uk BiopharmaWatch en 2026-09-17T11:00:00.000Z Pulsenmore Expands Its Fertility Platform into the UK https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-psych-congress-2026-presentations BiopharmaWatch en 2026-09-17T11:00:00.000Z Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 https://www.biopharmawatch.com/news/KMDA/cdc-reports-increase-rabies-exposures-kamada-supply-kedrab BiopharmaWatch en 2026-09-17T11:00:00.000Z CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand https://www.biopharmawatch.com/news/INDV/indivior-pharmaceuticals-special-cash-dividend BiopharmaWatch en 2026-09-17T11:00:00.000Z Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-resubmission-fda-anaphylm BiopharmaWatch en 2026-09-17T11:00:00.000Z Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film https://www.biopharmawatch.com/news/TLSA/tiziana-signs-mou-with-kaimrc-for-clinical-trial BiopharmaWatch en 2026-09-17T11:00:00.000Z Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center https://www.biopharmawatch.com/news/GANX/gain-therapeutics-roth-healthcare-conference BiopharmaWatch en 2026-09-17T11:00:00.000Z Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference https://www.biopharmawatch.com/news/BMY/bms-sotyktu-efficacy-safety-psoriatic-arthritis BiopharmaWatch en 2026-09-17T10:59:00.000Z Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years https://www.biopharmawatch.com/news/ACH/accendra-health-names-kenneth-gardner-smith-ceo BiopharmaWatch en 2026-09-17T10:30:00.000Z Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth https://www.biopharmawatch.com/news/AEMD/aethlon-north-immunology-merger-atopic-dermatitis BiopharmaWatch en 2026-09-17T10:30:00.000Z Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-alignment-project-orbis-ost-her2 BiopharmaWatch en 2026-09-17T10:00:00.000Z OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program https://www.biopharmawatch.com/news/YI/111-inc-receives-preliminary-acquisition-proposal BiopharmaWatch en 2026-09-17T08:25:00.000Z 111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company https://www.biopharmawatch.com/news/UDOC/unidoc-health-ambulances-live-patient-video BiopharmaWatch en 2026-09-17T07:30:00.000Z UniDoc Health Equips San Juan, Puerto Rico Ambulances With Live Patient Video https://www.biopharmawatch.com/news/IPHA/innate-pharma-first-half-2026-business-update BiopharmaWatch en 2026-09-17T05:00:00.000Z Innate Pharma Reports First Half 2026 Business Update and Financial Results https://www.biopharmawatch.com/news/IPHA/sobi-innate-partnership-effective-closing-conditions BiopharmaWatch en 2026-09-17T03:28:00.000Z Sobi and Innate announce partnership is now effective following completion of closing conditions https://www.biopharmawatch.com/news/VCRE/vicore-pharma-stifel-2026-forum BiopharmaWatch en 2026-09-17T02:20:00.000Z Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/BWIN/baldwin-insurance-group-investigation BiopharmaWatch en 2026-09-16T23:17:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of The Baldwin Insurance Group, Inc. (NASDAQ: BWIN) https://www.biopharmawatch.com/news/FSHP/investigation-flag-ship-acquisition-corporation BiopharmaWatch en 2026-09-16T23:15:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Flag Ship Acquisition Corporation (NASDAQ: FSHP) https://www.biopharmawatch.com/news/A/agilent-announces-cash-dividend-25-5-cents BiopharmaWatch en 2026-09-16T22:59:00.000Z CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-inducement-grants-cmo BiopharmaWatch en 2026-09-16T21:33:00.000Z AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LGVN/longeveron-elpis-ii-trial-results-hlhs BiopharmaWatch en 2026-09-16T21:27:00.000Z Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) https://www.biopharmawatch.com/news/HALO/halozyme-proposed-offering-convertible-senior-notes BiopharmaWatch en 2026-09-16T20:30:00.000Z Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 https://www.biopharmawatch.com/news/PNTG/pennant-acquires-mainplace-senior-living-orange-california BiopharmaWatch en 2026-09-16T20:30:00.000Z Pennant Acquires Real Estate of Mainplace Senior Living in Orange, California https://www.biopharmawatch.com/news/BRVE/braveheart-bio-participate-stifel-cardiometabolic-forum BiopharmaWatch en 2026-09-16T20:30:00.000Z Braveheart Bio to Participate in Stifel Cardiometabolic Forum https://www.biopharmawatch.com/news/A/agilent-announces-quarterly-dividend-25-5-cents BiopharmaWatch en 2026-09-16T20:15:00.000Z Agilent Announces Cash Dividend of 25.5 Cents per Share https://www.biopharmawatch.com/news/MDAI/spectral-ai-deepview-system-burn-indication-srbc BiopharmaWatch en 2026-09-16T20:15:00.000Z Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference https://www.biopharmawatch.com/news/BIIB/biogen-third-quarter-2026-financial-results BiopharmaWatch en 2026-09-16T20:06:00.000Z Biogen to Report Third Quarter 2026 Financial Results October 28, 2026 https://www.biopharmawatch.com/news/GOSS/gossamer-bio-appoints-greg-ciongoli-board BiopharmaWatch en 2026-09-16T20:01:00.000Z Gossamer Bio Appoints Greg Ciongoli to Board of Directors https://www.biopharmawatch.com/news/AVLN/avalyn-appoints-robert-meyer-board-directors BiopharmaWatch en 2026-09-16T20:01:00.000Z Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors https://www.biopharmawatch.com/news/IPHA/innate-sobi-partnership-effective-closing-conditions BiopharmaWatch en 2026-09-16T20:00:00.000Z Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions https://www.biopharmawatch.com/news/MOH/molina-donates-trauma-informed-care-iowa-youth BiopharmaWatch en 2026-09-16T18:00:00.000Z The MolinaCares Accord and Molina Healthcare of Iowa Donate $50,000 to Expand Trauma-Informed Care for Iowa Youth